BioMarin Pharmaceutical shares plummeted by a third after U.S. regulators rejected their potentially game-changing gene therapy for hemophilia A patients Due to LINDA A. JOHNSON AP Medical Writer 19 August 2020, 19:23 4 min reading Share on FacebookShare on TwitterEmail this article FAIRLESS HILLS, PA – Investors fled drug developer …
Read More »FDA blocks much anticipated BioMarin hemophilia gene therapy
